6 Minute Read
Market access leaders from DBV Technologies, Karyopharm Therapeutics, and Sesen Bio discuss critical factors in a successful launch and ways to achieve pre-launch forecasts.
4 Minute Read
In his second unification-focused blog, President and COO Josh Halpern discusses IntegriChain's investment in customer support to better augment the value for customers and end-users.
5 Minute Read
Solutions to common challenges that manufacturers face when commercializing rare and orphan disease therapies.
5 Minute Read
And other regulatory updates on Line Extension guidance, the upcoming DUNS number transition, and emergency 340B flexibilities.
4 Minute Read
President and COO Josh Halpern discusses the current and future capabilities of the integrated applications, analytics, and datastores within the ICyte Platform.
2 Minute Read
How manufacturers can leverage successful returns and inventory pipeline reserve methodologies for long-term benefits.
4 Minute Read
Potential and pending regulatory changes in 2022 including the current status of the Build Back Better Act and Part D Benefit Design.
2 Minute Read
Our newly combined team of commercialization experts focuses on solving your biggest access challenges: patient funnel pull-through and GTN optimization.
3 Minute Read
We ask market access leaders what they would change if they had the ability to launch their therapy all over again.